Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
32.51
-4.22 (-11.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals
January 03, 2023
Via
Benzinga
Why Are Apellis Pharmaceuticals Shares Falling Today?
November 04, 2022
Via
Benzinga
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
January 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
December 16, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
November 23, 2022
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.
Via
Benzinga
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 22, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
November 21, 2022
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday.
Via
Benzinga
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
November 21, 2022
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
November 18, 2022
Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 18, 2022
Via
Benzinga
Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease
November 18, 2022
Via
Benzinga
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
November 18, 2022
The delay is at Apellis' behest. The company wanted to include updated data in its request.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 18, 2022
Via
Benzinga
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
November 18, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
November 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
November 10, 2022
Upgrades
Via
Benzinga
5 Analysts Have This to Say About Apellis Pharmaceuticals
November 08, 2022
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter:
Via
Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Yelp, Twilio, Atlassian, And Other Big Losers From Friday
November 07, 2022
U.S. stocks closed higher on Friday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
November 04, 2022
Apellis long said it wouldn't wait for 24-month data for its eye drug. Apellis was wrong.
Via
Investor's Business Daily
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
November 07, 2022
Gainers
Via
Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
November 04, 2022
Gainers
Via
Benzinga
Why Starbucks Shares Are Trading Higher; Here Are 43 Stocks Moving Premarket
November 04, 2022
Gainers Sentage Holdings Inc. (NASDAQ: SNTG) shares rose 67.7% to $5.10 in pre-market trading after jumping 24% on Thursday.
Via
Benzinga
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
November 03, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.